Clinical Trials Browser

Lung Neoplasms

NCT06276933 2024-02-26

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 4 Not yet recruiting

104 enrolled

Thoracic

Lung Neoplasms

NCT06241807 2024-02-14

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

89 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05825443 2023-04-25

PANORAMA

Phase 2 Recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Phase 2 Unknown

63 enrolled

Thoracic

Adenocarcinoma of Lung

NCT05532527 2022-09-08

NSCLC

Phase NA Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05330065 2022-04-15

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Phase 1/2 Unknown

55 enrolled

Thoracic

Pleural Effusion, Malignant

NCT05053802 2021-09-23

MAGIC

Phase 2 Recruiting

146 enrolled

Thoracic

Multiple Primary Lung Cancer

NCT04291092 2021-09-10

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Phase 2 Unknown

63 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04943029 2021-09-02

NEOSUN

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05001412 2021-08-12

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Phase 1 Unknown

36 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04950400 2021-07-06

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Phase NA Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04541251 2021-06-23

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04828395 2021-05-11

F&C

Phase 2 Unknown

65 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04793139 2021-03-11

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Unknown

1,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04790539 2021-03-10

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Phase 2 Unknown

71 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04768075 2021-02-24

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Unknown

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04631146 2020-11-17

Efficacy and Safety of Camrelizumab in Real-World Study

Unknown

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04506242 2020-09-09

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Phase 2 Unknown

74 enrolled

Thoracic

NSCLC

NCT04453930 2020-07-01

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Phase 2 Unknown

60 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04425135 2020-06-11

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Phase 2 Unknown

59 enrolled

Thoracic

Lung Neoplasms

NCT04303130 2020-03-10

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Phase 2 Unknown

52 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03557411 2020-02-05

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Phase 2 Unknown

42 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04167774 2019-11-22

Compass-001

Phase 2 Unknown

62 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Phase 1/2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04108013 2019-09-27

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Phase 2 Unknown

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03601598 2018-07-26

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Phase 1/2 Unknown

41 enrolled

Thoracic

CRC

NCT03527251 2018-05-30

SEQUENCE

Phase 1 Unknown

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

PANORAMA

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

NSCLC

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

MAGIC

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

NEOSUN

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

F&C

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Efficacy and Safety of Camrelizumab in Real-World Study

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Compass-001

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

SEQUENCE